• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.《危重症合并肾脏替代治疗患者抗菌药物剂量调整指南》
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00583-19. Print 2019 Aug.
2
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.接受肾脏替代治疗患者抗菌治疗的药代动力学考量
Clin Pharmacokinet. 2007;46(12):997-1038. doi: 10.2165/00003088-200746120-00003.
3
Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy.应用药代动力学/药效学原理优化连续性肾脏替代治疗期间的抗菌治疗。
Anaesthesiol Intensive Ther. 2017;49(5):412-418. doi: 10.5603/AIT.a2017.0071. Epub 2017 Nov 24.
4
[Pharmacokinetics of antibiotics in continuous renal replacement therapies (CRRT)].[抗生素在连续性肾脏替代治疗(CRRT)中的药代动力学]
G Ital Nefrol. 2012 Jul-Aug;29(4):425-44.
5
Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.接受持续肾脏替代疗法或间歇性血液透析的成年危重症患者的抗菌药物给药概念及建议
Pharmacotherapy. 2009 May;29(5):562-77. doi: 10.1592/phco.29.5.562.
6
Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy.危重症患者持续肾脏替代治疗期间的药代动力学及抗菌药物剂量调整
Clin Nephrol. 2007 May;67(5):267-84. doi: 10.5414/cnp67267.
7
Drug dosing in continuous renal replacement therapy: general rules.连续性肾脏替代治疗中的药物剂量:一般规则。
Curr Opin Crit Care. 2007 Dec;13(6):645-51. doi: 10.1097/MCC.0b013e3282f0a3d3.
8
[Pharmacokinetic principles and drug-dosing adjustments during continuous renal replacement therapies (CRRT)].[连续性肾脏替代治疗(CRRT)期间的药代动力学原理及药物剂量调整]
G Ital Nefrol. 2006 May-Jun;23 Suppl 36:S127-38.
9
Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.儿童连续肾脏替代治疗中常用药物的药代动力学:当前文献的系统评价。
Clin Pharmacokinet. 2022 Feb;61(2):189-229. doi: 10.1007/s40262-021-01085-z. Epub 2021 Nov 30.
10
The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?急性肾损伤对重症患者抗菌药物剂量的影响:是否总是需要降低剂量?
Diagn Microbiol Infect Dis. 2014 May;79(1):77-84. doi: 10.1016/j.diagmicrobio.2014.01.015. Epub 2014 Jan 24.

引用本文的文献

1
Sulbactam Concentration in Critically Ill Patients with Hospital-Acquired Pneumonia: A Comparisons Stratified by Normal and Augmented Renal Clearance.医院获得性肺炎重症患者的舒巴坦浓度:按正常和增强肾清除率分层的比较
Infect Drug Resist. 2025 Sep 4;18:4731-4739. doi: 10.2147/IDR.S538120. eCollection 2025.
2
Pharmacotherapy variability and precision medicine in neurocritical care.神经重症监护中的药物治疗变异性与精准医学
Front Neurol. 2025 Jul 18;16:1630163. doi: 10.3389/fneur.2025.1630163. eCollection 2025.
3
Population pharmacokinetic analysis of remimazolam after continuous infusion for sedation in critically ill patients.重症患者持续输注瑞马唑仑镇静后的群体药代动力学分析。
Front Pharmacol. 2025 Jul 9;16:1526266. doi: 10.3389/fphar.2025.1526266. eCollection 2025.
4
Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy.替考拉宁的群体药代动力学及基于持续肾脏替代疗法的脓毒症患者剂量优化
Front Pharmacol. 2025 Jul 1;16:1621959. doi: 10.3389/fphar.2025.1621959. eCollection 2025.
5
Infections and mortality in ICU patients undergoing continuous renal replacement therapy: a retrospective cohort study.接受持续肾脏替代治疗的重症监护病房患者的感染与死亡率:一项回顾性队列研究。
BMC Nephrol. 2025 Jul 1;26(1):321. doi: 10.1186/s12882-025-04272-3.
6
Guidelines for hospital nephrology assistance from the Brazilian Society of Nephrology (BSN).巴西肾脏病学会(BSN)的医院肾脏病援助指南。
J Bras Nefrol. 2025 Jul-Sep;47(3):e20240239. doi: 10.1590/2175-8239-JBN-2024-0239en.
7
A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations.成人人群中黏菌素和多黏菌素B药代动力学研究的系统评价
Clin Pharmacokinet. 2025 May;64(5):655-689. doi: 10.1007/s40262-025-01488-2. Epub 2025 Apr 17.
8
Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives.体外血液净化疗法在脓毒症中的应用:当前模式、现有证据及未来展望
Crit Care. 2024 Dec 25;28(1):432. doi: 10.1186/s13054-024-05220-7.
9
Global research trends in therapeutic drug monitoring of antimicrobials from 2000 to 2023: a bibliometric analysis.2000年至2023年抗菌药物治疗药物监测的全球研究趋势:一项文献计量分析
Front Pharmacol. 2024 Dec 3;15:1474878. doi: 10.3389/fphar.2024.1474878. eCollection 2024.
10
Assessment of the Workflow and Time to Antibiotic Dose Adjustment for Critically Ill Patients Starting Continuous Renal Replacement Therapy.对开始接受连续性肾脏替代治疗的危重症患者抗生素剂量调整的工作流程和时间评估。
Hosp Pharm. 2024 Sep 12:00185787241274779. doi: 10.1177/00185787241274779.

本文引用的文献

1
Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy.连续肾脏替代治疗期间体外瑞他康唑的吸附和清除。
Blood Purif. 2018;46(3):214-219. doi: 10.1159/000489212. Epub 2018 Jun 14.
2
Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.使用蒙特卡洛模拟为接受混合血液透析的重症患者制定万古霉素给药方案。
SAGE Open Med. 2018 May 11;6:2050312118773257. doi: 10.1177/2050312118773257. eCollection 2018.
3
A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.蒙特卡洛模拟法在接受长时间间断肾脏替代治疗的危重症患者中β-内酰胺类药物给药的应用。
J Clin Pharmacol. 2018 Oct;58(10):1254-1265. doi: 10.1002/jcph.1137. Epub 2018 May 10.
4
Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.哌拉西林在持续低效透析的危重症成人中的群体药代动力学。
Ann Pharmacother. 2018 Oct;52(10):965-973. doi: 10.1177/1060028018773771. Epub 2018 May 7.
5
Population pharmacokinetics of daptomycin in critically ill patients.重症患者中达托霉素的群体药代动力学。
Int J Antimicrob Agents. 2018 Aug;52(2):158-165. doi: 10.1016/j.ijantimicag.2018.03.008. Epub 2018 Mar 20.
6
Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.危重症患者接受长时间间断肾脏替代治疗时万古霉素的群体药代动力学。
Int J Antimicrob Agents. 2018 Aug;52(2):151-157. doi: 10.1016/j.ijantimicag.2018.03.001. Epub 2018 Mar 9.
7
Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.针对急性肾损伤危重症患者及连续性肾脏替代治疗的改良多黏菌素方案
Chemotherapy. 2018;63(1):35-38. doi: 10.1159/000484974. Epub 2017 Dec 22.
8
Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury.脓毒症相关性急性肾损伤发病机制的最新进展。
J Nephrol. 2018 Jun;31(3):351-359. doi: 10.1007/s40620-017-0452-4. Epub 2017 Dec 23.
9
Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.长程与短程静脉输注抗假单胞菌β-内酰胺类药物治疗脓毒症患者的随机对照试验的系统评价和荟萃分析。
Lancet Infect Dis. 2018 Jan;18(1):108-120. doi: 10.1016/S1473-3099(17)30615-1. Epub 2017 Nov 5.
10
Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.不同肾脏替代方式对危重症患者连续输注哌拉西林他唑巴坦清除率的影响。
Int J Antimicrob Agents. 2017 Aug;50(2):227-231. doi: 10.1016/j.ijantimicag.2017.03.018. Epub 2017 Jul 6.

《危重症合并肾脏替代治疗患者抗菌药物剂量调整指南》

A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

机构信息

UO Dialisi, Azienda Ospedaliero-Universitaria Policlinico Umberto I, "Sapienza" Università di Roma, Rome, Italy.

UO Dialisi, Azienda Ospedaliero-Universitaria Policlinico Umberto I, "Sapienza" Università di Roma, Rome, Italy

出版信息

Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00583-19. Print 2019 Aug.

DOI:10.1128/AAC.00583-19
PMID:31109983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6658763/
Abstract

A careful management of antimicrobials is essential in the critically ill with acute kidney injury, especially if renal replacement therapy is required. Acute kidney injury may lead to clinically significant modifications of drugs' pharmacokinetic parameters, and the need for renal replacement therapy represents a further variable that should be considered to avoid inappropriate antimicrobial therapy. The most important pharmacokinetic parameters, useful to determine the significance of extracorporeal removal of a given drug, are molecular weight, protein binding, and distribution volume. In many cases, the extracorporeal removal of antimicrobials can be relevant, with a consistent risk of underdosing-related treatment failure and/or potential onset of bacterial resistance. It should also be taken into account that renal replacement therapies are often not standardized in critically ill patients, and their impact on plasma drug concentrations may substantially vary in relation to membrane characteristics, treatment modality, and delivered dialysis dose. Thus, in this clinical scenario, the knowledge of the pharmacokinetic and pharmacodynamic properties of different antimicrobial classes is crucial to tailor maintenance dose and/or time interval according to clinical needs. Finally, especially for antimicrobials known for a tight therapeutic range, therapeutic drug monitoring is strongly suggested to guide dosing adjustment in complex clinical settings, such as septic patients with acute kidney injury undergoing renal replacement therapy.

摘要

在伴有急性肾损伤的危重症患者中,对抗菌药物进行精细化管理至关重要,尤其是需要肾脏替代治疗的患者。急性肾损伤可能导致药物药代动力学参数发生具有临床意义的改变,而需要肾脏替代治疗则是另一个需要考虑的变量,以避免不恰当的抗菌治疗。最重要的药代动力学参数,有助于确定某种药物体外清除的重要性,包括分子量、蛋白结合率和分布容积。在许多情况下,抗菌药物的体外清除可能具有重要意义,存在与剂量不足相关的治疗失败和/或潜在细菌耐药风险。还应考虑到,危重症患者的肾脏替代治疗通常不规范,其对血浆药物浓度的影响可能因膜特性、治疗方式和给予的透析剂量而有很大差异。因此,在这种临床情况下,了解不同抗菌药物类别的药代动力学和药效动力学特性对于根据临床需求调整维持剂量和/或间隔时间至关重要。最后,特别是对于治疗窗较窄的抗菌药物,强烈建议进行治疗药物监测以指导在复杂临床情况下(例如伴有急性肾损伤的脓毒症患者进行肾脏替代治疗)进行剂量调整。